[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscle-disuse\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscle-disuse":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100394448","immune-cells-during-disuse-and-recovery-100394448",false,"NCT04416191","Immune Cells During Disuse and Recovery","Muscle Immune Cells During Disuse and Recovery in Aging and Metabolic Disease","Inclusion Criteria:\n\n1. Age between 18-35 and 60-85 yrs\n2. Ability to sign informed consent\n3. Free-living, prior to admission\n\nExclusion Criteria:\n\n* History of cardiovascular disease (e.g., CHF, CAD, right-to-left shunt)\n* History of endocrine or metabolic disease such as hypo\u002Fhyperthyroidism and diabetes\n* History of kidney disease or failure\n* Vascular disease\n* Risk of DVT including family history of thrombophilia, DVT, pulmonary emboli, myeloproliferative diseases including polycythemia (Hb\\>18 g\u002FdL) or thrombocytosis (platelets\\>400x103\u002FmL), and connective tissue diseases (positive lupus anticoagulant), hyperhomocystinemia, deficiencies of factor V Leiden, proteins S and C, and antithrombine III\n* Use of anticoagulant therapy (e.g., Coumadin, heparin)\n* Elevated systolic pressure \\>150 or a diastolic blood pressure \\> 100\n* Implanted electronic devices (e.g., pacemakers, electronic infusion pumps, stimulators)\n* Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma\n* Currently on a weight-loss diet\n* Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular\u002Ftopical\u002Finhaled therapeutic or physiologic doses of corticosteroids are permitted)\n* Androgens or growth hormone within 6 months of enrollment and for study duration (topical physiologic androgen replacement is permitted)\n* History of stroke with motor disability\n* A recent history (\\\u003C12 months) of GI bleed\n* History of liver disease\n* History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)\n* Pregnancy as determined by a pregnancy test\n* Any staff members who report directly to an investigator or who report to someone who reports directly to an investigator.\n* Any other condition or event considered exclusionary by the PI and faculty physician",true,"ALL","18 Years","85 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25],"NA","This is an interventional study enrolling healthy individuals aged 18-35 and 60-85 to understand the recovery of muscle health following a period of inactivity. The enrollment goal is 45 participants. The study will occur over the course of 1-2 months where participants will undergo testing before and after a 2-week limb immobilization period.",[28],"Muscle Disuse","RECRUITING","2025-12-01",{"date":32,"type":33},"2025-12-05","ACTUAL",{"date":35,"type":33},"2022-05-15",{"date":37,"type":22},"2028-04-30",{"name":39,"class":40},"University of Utah","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100598279","muscle-response-to-different-amounts-of-dietary-protein-during-leg-immobilization-100598279","NCT07069426","Muscle Response to Different Amounts of Dietary Protein During Leg Immobilization","The Effects of Varying Protein Intakes on Muscle Protein Synthesis During Injury-Mediated Muscle Disuse","Inclusion Criteria:\n\n* Men and women aged 18-39 years (17-39 years if military personnel)\n* Body mass index (BMI) between 18.5-32 kg\u002Fm2\n* Routinely participate in aerobic and\u002For resistance exercise at least 2 days per week.\n* Willing to refrain from alcohol, smoking, smokeless nicotine products (includes e-cigarettes, vaping, chewing tobacco), and dietary supplements (i.e., vitamin D, probiotics) 24 hours before and during immobilization and final testing day.\n* Willing to only consume caffeine products provided by study staff during the study.\n* Supervisor approval for federal civilian employees and non-SRV active-duty military personnel stationed at NSSC.\n* Biological females must have normal menstrual cycles between 26-32 days in duration; 5 menstrual cycles within the past 6 months; or on continuous hormonal contraception (i.e., IUD or oral contraceptives without placebo).\n\nExclusion Criteria:\n\n* Musculoskeletal injuries that may interfere with the safe use of crutches.\n* Personal or family history of thrombosis, or prior diagnosis of deep vein thrombosis (DVT) or pulmonary embolism (PE).\n* Metabolic or cardiovascular abnormalities, gastrointestinal disorders, neuromuscular disorders, lower-limb amputation, or muscle\u002Fbone wasting disorders (e.g., diabetes, cardiovascular disease, Crohn's disease, etc.).\n* Taking medication that affects macronutrient utilization (i.e., statins, corticosteroids, weight loss medications such as Ozempic, etc.).\n* Significantly abnormal blood clotting as determined by USARIEM Office of Medical Oversight (OMSO) or home duty station medical support (HMS).\n* Allergy to lidocaine (or similar local anesthetic).\n* Present condition of alcoholism, anabolic steroid use, or other substance abuse issues as determined by OMSO or HMS.\n* Blood donation within 8-wk of beginning the study.\n* Pregnant, trying to become pregnant, and\u002For breastfeeding (results of urine pregnancy test and self-report for breastfeeding will be obtained before body composition testing).\n* Unwilling or unable to consume study diets or foods provided due to personal preference and\u002For food allergies.\n* Unwilling or unable to adhere to study physical restrictions (i.e., no structured physical activity or recreational activity beyond activities of daily living) 24 hours before and during immobilization, and the final testing day.\n* Unwilling or unable to keep the knee brace on and walk with crutches during the immobilization phase.","17 Years","39 Years",{"count":52,"type":22},28,[25],"Individuals who sustain musculoskeletal injuries (MSKI) can experience a rapid loss of muscle mass due to declines in muscle loading and activation that occur post-injury (i.e., disuse atrophy). Loss of muscle under these conditions is attributed to a persistent negative net muscle protein balance (muscle protein synthesis \\[MPS\\] \\\u003C muscle protein breakdown) that results, in part, from declines in postprandial MPS (i.e., anabolic resistance). Nutritional interventions that enhance postprandial MPS may be used to overcome disuse-induced anabolic resistance and preserve muscle mass to accelerate recovery and improve recovery outcomes. While supplemental protein has been explored as a potential countermeasure to disuse-induce anabolic resistance, the observed efficacy of such interventions has been mixed. Equivocal findings across studies may be attributed, in part, to an insufficient understanding of what constitutes an effective protein-based intervention. Importantly, no study to date has determined an optimal protein dose for overcoming disuse-induce anabolic resistance, or if there is a threshold for maximally stimulating postprandial MPS under disuse conditions. Therefore, the objective of this work is to determine rates of MPS at rest and in response to standard (20 g) or high (40 g) doses of whey protein during knee immobilization (DISUSE) compared with standard activity (ACTIVE)",[28,56],"Muscle Disuse Atrophy",[58,59,60,61,62,63],"muscle protein synthesis","muscle disuse","muscle disuse atrophy","immobilization","anabolic resistance","dose-response","2025-09-04",{"date":66,"type":33},"2025-09-11",{"date":68,"type":33},"2025-09-01",{"date":70,"type":22},"2026-09",{"name":72,"class":73},"United States Army Research Institute of Environmental Medicine","FED"]